Simplify's take
What believers are saying
- Wellmark's October 2026 materials show PrudentRx remains active across employer plans.
- FCPS's November 2026 plan keeps PrudentRx for 2026 specialty-drug savings.
- Specialty-drug inflation and manufacturer copay programs keep PrudentRx relevant in 2026.
What critics are saying
- The July 2026 Gluesing lawsuit attacks PrudentRx's rebate capture model and patient trust.
- CVS Caremark arbitration wins do not erase state consumer-protection litigation or discovery risk.
- If employers force opt-outs, PrudentRx loses volume and becomes a removable middleman.
What makes PrudentRX unique
- PrudentRx embeds itself inside employer drug benefits, steering specialty copay enrollment.
- Its CVS Specialty and Caremark integration creates a sticky channel on every refill.
- Wellmark and FCPS still deploy PrudentRx in 2026, proving insurer and employer adoption.
Help us improve and share your feedback! Did you find this helpful?